Tag Archives: NLNK

Analysts’ View: NewLink Genetics (NLNK), Zumiez (ZUMZ), Zions Bancorp (ZION)

Investment Analysts at Robert W. Baird upgraded NewLink Genetics Corp. (NASDAQ:NLNK) shares from Neutral to Outperform rating while increasing their price target from $8 to $22.

NewLink Genetics Corp. is a clinical stage immuno-oncology company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians.


Zumiez Inc. (NASDAQ:ZUMZ) shares were upgraded by analysts at B. Riley & Co. from Neutral to Buy rating.

Zumiez, Inc. is a multi-channel retailer of apparel, footwear, accessories and hardgoods rooted in youth culture as expressed through music, art, fashion and action sports lifestyle for young men and women.


Brokerage Firm Robert W. Baird upgraded Zions Bancorp (NASDAQ:ZION) shares from Underperform to Neutral rating with a price target of $43.

Zions Bancorp. engages int he provision of banking and related services and offers a variety of commercial and retail banking and mortgage lending products and services.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://www.crwe.info/disclaimer/